How is non-obviousness in improvement drug invention patents assessed?
Wu Xiaoping and Hu Honghui of Wanhuida examine the methodology employed by the Patent Reexamination Board to determine non-obviousness of an improvement invention
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: